Integrated Filing — IndAS


General information about company

Scrip Code 532983
NSE Symbol RPGLIFE
MSEI Symbol NOTLISTED
ISIN INE105J01010
Name of company RPG Life Sciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 28-Apr-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 21-Apr-2024
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceutical
Start date and time of board meeting 28-Apr-2025   15:00:00
End date and time of board meeting 28-Apr-2025   18:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-01-24
Indicate Company website link for updated RPT policy of the Company https://www.rpglifesciences.com/website/index.php
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no such default



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1430900000 6534300000
Other income 50600000 126800000
Total income 1481500000 6661100000
2 Expenses
(a) Cost of materials consumed 268900000 1102600000
(b) Purchases of stock-in-trade 212200000 951400000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 6100000 86100000
(d) Employee benefit expense 316000000 1261400000
(e) Finance costs 1800000 6200000
(f) Depreciation, depletion and amortisation expense 53700000 214300000
(f) Other Expenses
1 Other Expenses 372800000 1536300000
Total other expenses 372800000 1536300000
Total expenses 1231500000 5158300000
3 Total profit before exceptional items and tax 250000000 1502800000
4 Exceptional items 1099000000 826000000
5 Total profit before tax 1349000000 2328800000
6 Tax expense
7 Current tax 174800000 496900000
8 Deferred tax 700000 -500000
9 Total tax expenses 175500000 496400000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 1173500000 1832400000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 1173500000 1832400000
17 Other comprehensive income net of taxes -11500000 -11000000
18 Total Comprehensive Income for the period 1162000000 1821400000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 132300000 132300000
Face value of equity share capital 8 8
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 70.96 110.8
Diluted earnings (loss) per share from continuing operations 0 0
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 70.96 110.8
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 70.96 110.8
Diluted earnings (loss) per share from continuing and discontinued operations 70.96 110.8
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1611800000
Capital work-in-progress 39500000
Investment property 0
Goodwill 0
Other intangible assets 106500000
Intangible assets under development 121100000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 10100000
Trade receivables, non-current 0
Loans, non-current 1700000
Other non-current financial assets 4300000
Total non-current financial assets 16100000
Deferred tax assets (net) 10000000
Other non-current assets 5000000
Total non-current assets 1910000000
2 Current assets
Inventories 929800000
Current financial asset
Current investments 1259000000
Trade receivables, current 867600000
Cash and cash equivalents 287000000
Bank balance other than cash and cash equivalents 1109100000
Loans, current 0
Other current financial assets 57900000
Total current financial assets 3580600000
Current tax assets (net) 15600000
Other current assets 142100000
Total current assets 4668100000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 6578100000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 132300000
Other equity 5173000000
Total equity attributable to owners of parent 5305300000
Non controlling interest
Total equity 5305300000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 29100000
Total non-current financial liabilities 29100000
Provisions, non-current 45400000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 74500000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 36600000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 757300000
Total Trade payable 793900000
Other current financial liabilities 176300000
Total current financial liabilities 970200000
Other current liabilities 67000000
Provisions, current 161100000
Current tax liabilities (Net) 0
Deferred government grants, Current 0
Total current liabilities 1198300000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 1272800000
Total equity and liabilites 6578100000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to Profit or Loss -15400000 -14700000
Total Amount of items that will not be reclassified to profit and loss -15400000 -14700000
2 Income tax relating to items that will not be reclassified to profit or loss -3900000 -3700000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -11500000 -11000000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2328800000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 6200000
Adjustments for decrease (increase) in inventories 61900000
Adjustments for decrease (increase) in trade receivables, current -357500000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 61000000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current -7600000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 95400000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 214300000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -16200000
Adjustments for provisions, non-current 29900000
Adjustments for other financial liabilities, current -158500000
Adjustments for other financial liabilities, non-current 14700000
Adjustments for unrealised foreign exchange losses gains -2800000
Adjustments for dividend income 0
Adjustments for interest income 32100000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) -47500000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) -872600000
Other adjustments for non-cash items -11300000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -1022700000
Net cash flows from (used in) operations 1306100000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 527500000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 778600000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1094700000
Purchase of property, plant and equipment 360300000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 32100000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -1184500000
Net cash flows from (used in) investing activities -418000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 0
Dividends paid 264600000
Interest paid 6200000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -270800000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 89800000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 89800000
Cash and cash equivalents cash flow statement at beginning of period 197200000
Cash and cash equivalents cash flow statement at end of period 287000000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 SR BC & CO LLP Yes 28-Feb-2026


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 RPG Life Sciences Limited Mr. Yugal Sikri Managing Director Remuneration 70000000 Nil 0 0 0 Textual Information(1)
2 RPG Life Sciences Limited Mr. Vishal Shah Chief Financial Officer Remuneration Nil 0 0 0
3 RPG Life Sciences Limited Mr. Rajesh Shirambekar Company Secretary Remuneration Nil 0 0 0
4 RPG Life Sciences Limited RPG Enterprises Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 12000000 Nil 0 0 0
5 RPG Life Sciences Limited RPG Enterprises Limited Entities where control / significant influence by KMPs and their relatives exists Any other transaction Payment made/reimbursement of expenses to related party 8850000 Nil 0 0 0
6 RPG Life Sciences Limited Ceat Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 17500000 Nil 0 0 0 Textual Information(2)
7 RPG Life Sciences Limited Ceat Limited Entities where control / significant influence by KMPs and their relatives exists Any other transaction Payment made/reimbursement of expenses to related party 2900000 Nil 0 0 0
8 RPG Life Sciences Limited KEC international Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 200000000 Nil 0 0 0 Textual Information(3)
9 RPG Life Sciences Limited KEC international Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 800000 Nil 0 0 0 Textual Information(4)
10 RPG Life Sciences Limited KEC international Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 250000 Nil 0 0 0
11 RPG Life Sciences Limited Zensar Technologies Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services 5000000 Nil 0 0 0
12 RPG Life Sciences Limited Mr. Harsh V. Goenka Chairman- Non-Executive Non-Independent Director Remuneration Nil 0 0 0 Textual Information(5)
13 RPG Life Sciences Limited Mr. Manoj Maheshwari Non Executive Director Remuneration Nil 0 0 0 Textual Information(6)
14 RPG Life Sciences Limited Mr. Mahesh S. Gupta Non Executive Director Remuneration Nil 0 0 0 Textual Information(7)
15 RPG Life Sciences Limited Dr. Lalit S. Kanodia Non Executive Director Remuneration Nil 0 0 0 Textual Information(8)
16 RPG Life Sciences Limited Mr. Narendra Ambwani Non Executive Director Remuneration Nil 0 0 0 Textual Information(9)
17 RPG Life Sciences Limited Ms. Zahabiya Khorakiwala Non Executive Director Remuneration Nil 0 0 0 Textual Information(10)
18 RPG Life Sciences Limited Mr. Bhaskar Iyer Non Executive Director Remuneration Nil 0 0 0 Textual Information(11)
19 RPG Life Sciences Limited Mr. Sachin Nandgaonkar Non Executive Director Remuneration Nil 0 0 0 Textual Information(12)
20 RPG Life Sciences Limited Mr. Rajat Bhargava Non Executive Director Remuneration Nil 0 0 0 Textual Information(13)
21 RPG Life Sciences Limited Mr. Hiten Kotak Non Executive Director Remuneration Nil 0 0 0 Textual Information(14)
22 RPG Life Sciences Limited Mr. Anil Matai Non Executive Director Remuneration Nil 0 0 0 Textual Information(15)
23 RPG Life Sciences Limited Ms. Radhika Gupta Non Executive Director Remuneration Nil 0 0 0 Textual Information(16)
24 RPG Life Sciences Limited Mr. Bhaskar Iyer Non Executive Director Any other transaction Consultancy Fees paid to Non-Executive Director- Bhaskar Iyer Nil 0 0 0
25 RPG Life Sciences Limited RPG Life Sciences Limited Management Staff Superannuation Fund Entities where control / significant influence by KMPs and their relatives exists Any other transaction Contribution to Trusts Nil 0 0 0
26 RPG Life Sciences Limited RPG Life Sciences Limited Staff Gratuity Fund Entities where control / significant influence by KMPs and their relatives exists Any other transaction Contribution to Trusts Nil 0 0 0
27 RPG Life Sciences Limited RPG Life Sciences Limited Staff Gratuity Fund Entities where control / significant influence by KMPs and their relatives exists Any other transaction Contribution to Trusts Nil 0 0 0
28 RPG Life Sciences Limited Harrison Malayalam Limited Entities where control / significant influence by KMPs and their relatives exists Purchase of goods or services Nil 126000 0 0
Total value of transaction during the reporting period 126000



Text Block

Textual Information(1) Amount pertains to post employment benefits within the remuneration of Rs. 7 crores p.a. approved by the shareholders. Rs. 342.96 lakhs pertains to salary and Rs. 7.00 lakhs pertains to post employment benefits that excludes provision for gratuity and compensated absences,which is determined on the basis of acturial valuation done on overall basis of the Company and including PF and other benefits
Textual Information(2) Amount pertains to Service charge paid to related party for availment of services
Textual Information(3) Amount paid towards services availed from related party.
Textual Information(4) Amount pertains to Service charge paid to related party for availment of services
Textual Information(5) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(6) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(7) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(8) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(9) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(10) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(11) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(12) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(13) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(14) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(15) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.
Textual Information(16) Amount pertains to Sitting Fees paid to Directors within the overall limit of Rs. 70 Lakhs as approved by Audit Committee.


Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt